MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Levodopa(L-dopa)"

  • 2018 International Congress

    Dysphagia predicts poor outcome in late-stage Parkinson’s disease

    M. Fabbri, D. Abreu, L. Guedes, M. Rosa, A. Antonini, M. Zibetti, L. Lopiano, J. Fereira, M. Coelho (Lisbon, Portugal)

    Objective: to evaluate the clinical progression and prognostic factors of a late-stage PD (LSPD) population. Background: Parkinson’s disease (PD) disability milestones emerge in an exponential…
  • 2018 International Congress

    Personal KinetiGraph™ Movement Recording System: An Assessment of Utility in a Movement Disorder Clinic

    F. Nahab, H. Abuhussain, L. Moreno (La Jolla, CA, USA)

    Objective: The objective of this open-label study was to evaluate the clinical utility of the Personal KinetiGraph™ (PKG) Movement Recording System in the care of…
  • 2018 International Congress

    Levodopa effect on non-motor symptoms in late stage Parkinson’s disease

    K. Rosqvist, P. Odin, P. Hagell, S. Iwarsson, M. Nilsson, A. Storch (Lund, Sweden)

    Objective: To assess responsiveness of non-motor symptoms (NMS) to Levodopa (L-dopa) and to describe the NMS burden in late stage Parkinson's disease (PD). Moreover, to…
  • 2018 International Congress

    Gastric Retention of the Accordion Pill™: Results From MRI Studies With Parkinson’s Disease Patients and Healthy Volunteers

    N. Navon, R. Gendreau, J. Meckler (Jerusalem, Israel)

    Objective: To determine gastric retention (GR) of the Accordion Pill™ (AP) in patients with Parkinson’s disease (PD) and healthy volunteers. Background: While carbidopa/levodopa (CD/LD) is…
  • 2018 International Congress

    L-Dopa responsiveness in early Parkinson’s disease: Results from the United Kingdom Tracking Parkinson’s study

    N. Malek, S. Kanavou, M. Lawton, K. Grosset, V. Pitz, N. Bajaj, R. Barker, D. Burn, T. Foltynie, J. Hardy, N. Wood, N. Williams, H. Morris, Y. Ben-Shlomo, D. Grosset (Ipswich, United Kingdom)

    Objective: We wanted to evaluate L-dopa responsiveness in a large cohort of patients with recently diagnosed Parkinson’s disease (PD) using an acute L-dopa challenge test.…
  • 2018 International Congress

    High dose of levodopa and Segawa disease

    M. Taghiyeva (Baku, Azerbaijan)

    Objective: To analyze the dose-dependent effects of levodopa on the symptoms of the disease in our case. Background: In 1976, Segawa et al. reported dopa-responsive…
  • 2018 International Congress

    Effects of L-DOPA on Quantitative Gait Parameters Measured with Wearable Sensors

    M. Brys, J. Paskavitz, A. Dowling, V. Auclair, A. Wood, D. McLaren, R. Postuma, B. Bedell, J. Cedarbaum (Cambridge, MA, USA)

    Objective: To quantify and validate the ability of wearable sensors to detect response to symptomatic medication in Parkinson's Disease (PD). Background: While clinical visual assessment…
  • 2018 International Congress

    Intrastriatal Fyn silencing as a gene therapy strategy to manage levodopa induced dyskinesia in a mice model of Parkinson’s disease

    M. Bordone, A. Damianich, A. Bernardi, E. Avale, O. Gershanik, J. Ferrario (CABA, Argentina)

    Objective: To genetically abrogate Fyn expression to reduce levodopa induced dyskinesia (LID) in the 6-OHDA mice model of Parkinson’s disease (PD), using intrastriatal-injected lentiviral (LV)…
  • 2018 International Congress

    Design of a Pharmacokinetics Study with Multiple Doses of Accordion Pill™ Carbidopa/Levodopa in Patients with Parkinson’s disease

    C. Olanow, K. Kieburtz, J. Dubow, F. Stocchi, J. Meckler, N. Navon, R. Gendreau (Sarasota, FL, USA)

    Objective: To perform a pharmacokinetic (PK) study of the Accordion Pill™ carbidopa/levodopa (AP-CD/LD) and to determine if multiple doses can provide continuous delivery of LD.…
  • 2018 International Congress

    A phase Ib trial studying the safety and tolerability of IRL790 in patients with Parkinson’s disease and levodopa-induced dyskinesia

    P. Svenningsson, A. Johansson, D. Nyholm, P. Tsitsi, C. Sonesson, J. Tedroff (Stockholm, Sweden)

    Objective: The primary objective was to investigate the safety and tolerability of IRL790 in PD patients with LID in a randomized controlled trial. Background: IRL790…
  • « Previous Page
  • 1
  • …
  • 37
  • 38
  • 39
  • 40
  • 41
  • …
  • 57
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
    • #25062 (not found)
    • Welcome to the MDS Abstracts Site
    • Effect of marijuana on Essential Tremor: A case report
    • Advanced Search
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley